BioPharma-Reporter.com |
GSK set to kickstart asthma mAb sector after EU Nucala approval
BioPharma-Reporter.com This decline, coupled with the underperformance of more recently launched drugs – Breo and Anoro Ellipta – saw revenue generated by GSK's asthma franchise fall 10% to £6.1bn in 2014. GSK has not given a forecast for Nucala, but clearly it hopes the … |
View full post on asthma – Google News
